Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

BACKGROUND: Data from trials of vedolizumab for inflammatory bowel disease and from real-world studies suggest an exposure-response relationship, such that vedolizumab trough levels may predict clinical and endoscopic outcomes. OBJECTIVE: The purpose of this study was to evaluate in a prospective ob...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:United European Gastroenterol J
Autors principals: Guidi, Luisa, Pugliese, Daniela, Tonucci, Tommaso Panici, Bertani, Lorenzo, Costa, Francesco, Privitera, Giuseppe, Tolusso, Barbara, Di Mario, Clara, Albano, Eleonora, Tapete, Gherardo, Gremese, Elisa, Papa, Alfredo, Gasbarrini, Antonio, Rapaccini, Gian Ludovico, Armuzzi, Alessandro
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2019
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6826518/
https://ncbi.nlm.nih.gov/pubmed/31700632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2050640619873784
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars